-
EP3634469
European procedure
- EP About this file
- EP Legal status
- EP Federated register
- EP Event history
- EP Citations
- EP Patent family
- EP All documents
Extract from the Register of European Patents
EP About this file: EP3634469
| EP3634469 - METHODS FOR TREATING HYPERLIPIDEMIA IN DIABETIC PATIENTS BY ADMINISTERING A PCSK9 INHIBITOR [Right-click to bookmark this link] | Status | The application is deemed to be withdrawn Status updated on 22.07.2022 Database last updated on 09.04.2026 | |
| Former | Examination is in progress Status updated on 30.10.2020 | ||
| Former | Request for examination was made Status updated on 13.03.2020 | ||
| Former | The international publication has been made Status updated on 15.12.2018 | ||
| Former | unknown Status updated on 16.07.2018 | Most recent event Tooltip | 22.07.2022 | Application deemed to be withdrawn | published on 24.08.2022 [2022/34] | Applicant(s) | For all designated states Sanofi Biotechnology 54 rue La Boétie 75008 Paris / FR | [2020/16] | Inventor(s) | 01 /
BUJAS-BOBANOVIC, Maja c/o Sanofi 54 rue La Boétie 75008 Paris / FR | [2020/16] | Representative(s) | Zwicker, Jörk ZSP Patentanwälte PartG mbB Hansastraße 32 80686 München / DE | [2020/16] | Application number, filing date | 18737034.1 | 09.06.2018 | [2020/16] | WO2018IB54182 | Priority number, date | US201762517672P | 09.06.2017 Original published format: US 201762517672 P | US201762532162P | 13.07.2017 Original published format: US 201762532162 P | EP20180305565 | 04.05.2018 Original published format: EP 18305565 | [2020/16] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO2018225041 | Date: | 13.12.2018 | Language: | EN | [2018/50] | Type: | A1 Application with search report | No.: | EP3634469 | Date: | 15.04.2020 | Language: | EN | The application published by WIPO in one of the EPO official languages on 13.12.2018 takes the place of the publication of the European patent application. | [2020/16] | Search report(s) | International search report - published on: | EP | 13.12.2018 | Classification | IPC: | A61K38/28, A61K39/395, C07K16/40, A61K39/00 | [2020/16] | CPC: |
C07K16/40 (EP,IL,KR);
A61K38/28 (EP,IL);
A61K39/395 (EP,IL);
A61K45/06 (IL);
A61K9/0019 (IL);
A61P3/06 (KR);
A61P3/10 (IL,KR);
C12Y304/21062 (IL);
A61K2039/505 (EP,IL,KR);
| Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2020/16] | Title | German: | VERFAHREN ZUR BEHANDLUNG VON HYPERLIPIDÄMIE BEI DIABETESPATIENTEN DURCH VERABREICHUNG EINES PCSK9-HEMMERS | [2020/16] | English: | METHODS FOR TREATING HYPERLIPIDEMIA IN DIABETIC PATIENTS BY ADMINISTERING A PCSK9 INHIBITOR | [2020/16] | French: | MÉTHODES DE TRAITEMENT DE L'HYPERLIPIDÉMIE CHEZ DES PATIENTS DIABÉTIQUES PAR ADMINISTRATION D'UN INHIBITEUR DE PCSK9 | [2020/16] | Entry into regional phase | 08.01.2020 | National basic fee paid | 08.01.2020 | Designation fee(s) paid | 08.01.2020 | Examination fee paid | Examination procedure | 08.01.2020 | Examination requested [2020/16] | 08.01.2020 | Date on which the examining division has become responsible | 23.07.2020 | Amendment by applicant (claims and/or description) | 29.10.2020 | Despatch of a communication from the examining division (Time limit: M06) | 05.05.2021 | Reply to a communication from the examining division | 08.09.2021 | Despatch of a communication from the examining division (Time limit: M06) | 19.03.2022 | Application deemed to be withdrawn, date of legal effect [2022/34] | 11.04.2022 | Despatch of communication that the application is deemed to be withdrawn, reason: reply to the communication from the examining division not received in time [2022/34] | Fees paid | Renewal fee | 31.03.2020 | Renewal fee patent year 03 | 14.06.2021 | Renewal fee patent year 04 | 31.03.2022 | Renewal fee patent year 05 |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Cited in | International search | [XP] LAWRENCE A. LEITER ET AL: "Lipid-lowering efficacy and safety of alirocumab in patients with or without diabetes: A sub-analysis of ODYSSEY COMBO II : LEITER et al.", DIABETES, OBESITY AND METABOLISM, vol. 19, no. 7, 1 July 2017 (2017-07-01), pages 989 - 996, XP055496322, ISSN: 1462-8902, DOI: 10.1111/dom.12909 DOI: http://dx.doi.org/10.1111/dom.12909 | [I] DIRK MLLER-WIELAND ET AL: "Open Access", CARDIOVASC DIABETOL, vol. 16, 70, 1 January 2017 (2017-01-01), pages 1 - 10, XP055496324, Retrieved from the Internet DOI: http://dx.doi.org/10.1186/s12933â017â0552â4 | [Y] HELEN M. COLHOUN ET AL: "No effect of PCSK9 inhibitor alirocumab on the incidence of diabetes in a pooled analysis from 10 ODYSSEY Phase 3 studies", EUROPEAN HEART JOURNAL, vol. 37, no. 39, 26 July 2016 (2016-07-26), pages 2981 - 2989, XP055496367, ISSN: 0195-668X, DOI: 10.1093/eurheartj/ehw292 DOI: http://dx.doi.org/10.1093/eurheartj/ehw292 | [XP] LEITER L A: "Efficacy and safety of alirocumab ininsulion-treated individuals with type 1 or type 2 diabetes and high cardiovascular risk: The ODYSSEY DM-INSULIN randomized trial", DIABETES, OBESITY AND METABOLISM, vol. 19, 1 September 2017 (2017-09-01), pages 1781 - 1792, XP002783532, DOI: 10.1111/DOM.13114 DOI: http://dx.doi.org/10.1111/dom.13114 | [YP] ZHANG JUN ET AL: "Usefulness of alirocumab and evolocumab for te teatment of patients with diabetic dyslipidemia", BAYLOR UNIVERSITY MEDICAL CENTER PROCEEDINGS, vol. 31, no. 2, 1 April 2018 (2018-04-01), pages 180 - 184, XP002783533, DOI: 10.1080/08998280.2018.1441255 | [IP] MARC S SABATINE ET AL: "Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: a prespecified analysis of the FOURIER randomised controlled trial", THE LANCET / DIABETES & ENDOCRINOLOGY, vol. 5, no. 12, 1 December 2017 (2017-12-01), UK, pages 941 - 950, XP055496308, ISSN: 2213-8587, DOI: 10.1016/S2213-8587(17)30313-3 DOI: http://dx.doi.org/10.1016/S2213-8587(17)30313-3 | [Y] GIUSEPPE DELLA PEPA ET AL: "Alirocumab for the treatment of hypercholesterolaemia", EXPERT REVIEW OF CLINICAL PHARMACOLOGY, vol. 10, no. 6, 3 June 2017 (2017-06-03), EXPERT REVIEWS LTD. GBR, UK, pages 571 - 582, XP055496305, ISSN: 1751-2433, DOI: 10.1080/17512433.2017.1318063 DOI: http://dx.doi.org/10.1080/17512433.2017.1318063 | Examination | ANONYMOUS: "Lipid-lowering efficacy and safety of alirocumab in patients with or without diabetes: A sub-analysis of ODYSSEY COMBO II - PubMed", 18 April 2018 (2018-04-18), XP055836650, Retrieved from the Internet | by applicant | EP2387989 | US6596541 | US2010166768 | US8795669 | WO2013166448 | WO2012168491 | US9120851 | US8062640 | SHARRETT ET AL., CIRCULATION, vol. 104, 2001, pages 1108 - 1113 | BOERSMA; PLUCKTHUN, CURR. OPIN. BIOTECHNOL., vol. 22, 2011, pages 849 - 857 | TAYLOR ET AL., NUCL. ACIDS RES., vol. 20, 1992, pages 6287 - 6295 | ANGAL ET AL., MOLECULAR IMMUNOLOGY, vol. 30, 1993, pages 105 | "Remington's Pharmaceutical Sciences", MACK PUBLISHING COMPANY | POWELL ET AL.: "Compendium of excipients for parenteral formulations", J PHARM SCI TECHNOL, vol. 52, 1998, pages 238 - 311, XP009119027 | WU ET AL., J. BIOL. CHEM., vol. 262, 1987, pages 4429 - 4432 | SEFTON, CRC CRIT. REF. BIOMED. ENG., vol. 14, 1987, pages 201 | "Medical Applications of Controlled Release", 1974, CRC PRES. | GOODSON: "Medical Applications of Controlled Release", vol. 2, 1984, pages: 115 - 138 | LANGER, SCIENCE, vol. 249, 1990, pages 1527 - 1533 | "International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use", M3(R2): GUIDANCE ON NONCLINICAL SAFETY STUDIES FOR THE CONDUCT OF HUMAN CLINICAL TRIALS AND MARKETING AUTHORIZATION FOR PHARMACEUTICALS. ICH, June 2009 (2009-06-01), pages 1 - 25 | CHAN ET AL., ANN TRANSL MED., vol. 5, no. 23, 2017, pages 477 |